Dietary regulation of peroxisome proliferator-activated receptors in metabolic syndrome.

[1]  Haoyang Zou,et al.  Quercetin ameliorates hepatic fat accumulation in high-fat diet-induced obese mice via PPARs. , 2023, Food & function.

[2]  Jianxin Cao,et al.  Que Zui tea ameliorates hepatic lipid accumulation and oxidative stress in high fat diet induced nonalcoholic fatty liver disease. , 2022, Food research international.

[3]  J. Zhang,et al.  Recent advances in nuclear receptors-mediated health benefits of blueberry. , 2022, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[4]  R. Otton,et al.  Green tea extract increases adiponectin and PPARα levels to improve hepatic steatosis. , 2022, The Journal of nutritional biochemistry.

[5]  Metab Alharbi,et al.  Guggulsterone Mediated JAK/STAT and PPAR-Gamma Modulation Prevents Neurobehavioral and Neurochemical Abnormalities in Propionic Acid-Induced Experimental Model of Autism , 2022, Molecules.

[6]  S. Maheshwari,et al.  Immunomodulatory potential of phytochemicals and other bioactive compounds of fruits: A review , 2022, Food Frontiers.

[7]  Baojian Wu,et al.  PPAR-γ integrates obesity and adipocyte clock through epigenetic regulation of Bmal1 , 2022, Theranostics.

[8]  K. Krausz,et al.  Withaferin A alleviates ethanol-induced liver injury by inhibiting hepatic lipogenesis. , 2022, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[9]  Ya-Ping Liu,et al.  Hypoglycemic and hypolipidemic effects of Epigynum auritum in high fat diet and streptozotocin-induced diabetic rats. , 2022, Journal of ethnopharmacology.

[10]  Yuanjun He,et al.  The role of dietary flavonoids for modulation of ATP binding cassette transporter mediated multidrug resistance , 2021, eFood.

[11]  Anil K Sharma,et al.  Role of Phytoconstituents as PPAR Agonists: Implications for Neurodegenerative Disorders , 2021, Biomedicines.

[12]  Fatma Hadrich,et al.  Protective effect of olive leaves phenolic compounds against neurodegenerative disorders: Promising alternative for Alzheimer and Parkinson diseases modulation. , 2021, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[13]  E. Deeks.  Chiglitazar: First Approval , 2021, Drugs.

[14]  P. Pávek,et al.  Dietary phytochemicals as modulators of human pregnane X receptor , 2021, Critical reviews in food science and nutrition.

[15]  Zhongwen Yuan,et al.  Effects of cyclocarya paliurus flavonoid extract in non-alcoholic steatohepatitis mice: Intermeshing network pharmacology and in vivo pharmacological evaluation , 2021, Pharmacognosy Magazine.

[16]  Weili Zheng,et al.  Structural Basis for PPARs Activation by The Dual PPARα/γ Agonist Sanguinarine: A Unique Mode of Ligand Recognition , 2021, Molecules.

[17]  Jiaqi Liu,et al.  18:0 Lyso PC, a natural product with potential PPAR-γ agonistic activity, plays hypoglycemic effect with lower liver toxicity and cardiotoxicity in db/db mice. , 2021, Biochemical and biophysical research communications.

[18]  P. Pávek,et al.  A review on pharmacological activities and synergistic effect of quercetin with small molecule agents. , 2021, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[19]  T. Falla,et al.  Accelerated Barrier Repair in Human Skin Explants Induced with a Plant-Derived PPAR-α Activating Complex via Cooperative Interactions , 2021, Clinical, cosmetic and investigational dermatology.

[20]  S. Anderson,et al.  Systemic toxicity induced by topical application of heptafluorobutyric acid (PFBA) in a murine model. , 2021, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[21]  S. Luo,et al.  Synergistic effect of combined treatment with baicalin and emodin on DSS‐induced colitis in mouse , 2021, Phytotherapy research : PTR.

[22]  E. Santarém,et al.  Methoxyeugenol deactivates hepatic stellate cells and attenuates liver fibrosis and inflammation through a PPAR-ɣ and NF-kB mechanism. , 2021, Journal of ethnopharmacology.

[23]  M. Locatelli,et al.  Investigation into the biological properties, secondary metabolites composition, and toxicity of aerial and root parts of Capparis spinosa L.: An important medicinal food plant. , 2021, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[24]  Chunlei Zhu,et al.  Investigation on the binding of cyanobacterial metabolite calothrixin A with human serum albumin for evaluating its potential toxicology. , 2021, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[25]  Sameer Sharma,et al.  A Computational approach of phytochemicals from Bacopa monnieri in contrast to DPP-4 and peroxisome proliferator-activated receptors gamma as a Target for type-1 diabetes , 2021, World Journal of Biological and Pharmaceutical Research.

[26]  T. Nagano,et al.  Effect of a diet containing a mixture of soybean isoflavones and soyasaponins on contact hypersensitivity and gut microbiota in mice , 2021, Food Frontiers.

[27]  Jingbo Liu,et al.  Transcriptome analysis reveals the hepatoprotective mechanism of soybean meal peptides against alcohol-induced acute liver injury mice. , 2021, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[28]  O. Heikal,et al.  Possible role of rice bran extract in microglial modulation through PPAR-gamma receptors in alzheimer’s disease mice model , 2021, Metabolic Brain Disease.

[29]  G. Zheng,et al.  Chlorogenic acid and caffeine combination attenuates adipogenesis by regulating fat metabolism and inhibiting adipocyte differentiation in 3T3-L1 cells. , 2021, Journal of food biochemistry.

[30]  Balaji Meriga,et al.  A bioactive fraction of Pterocarpus santalinus inhibits adipogenesis and inflammation in 3T3-L1 cells via modulation of PPAR-γ/SREBP-1c and TNF-α/IL-6 , 2021, 3 Biotech.

[31]  Qifu Li,et al.  Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP). , 2021, Science Bulletin.

[32]  A. Bernardo,et al.  Curcumin promotes oligodendrocyte differentiation and their protection against TNF-α through the activation of the nuclear receptor PPAR-γ , 2021, Scientific reports.

[33]  R. Aluko.  Food-derived Acetylcholinesterase Inhibitors as Potential Agents against Alzheimer’s Disease , 2021 .

[34]  A. O. Ademiluyi,et al.  African mistletoe ( Tapinanthus bangwensis Lor.) infestation improves the phenolic constituents, antioxidative and antidiabetic effects of almond ( Terminalia catappa Linn.) host leaf in sucrose‐rich diet‐induced diabetic‐like phenotypes in fruit fly ( Drosophila melanogaster Meigen) , 2021, Food Frontiers.

[35]  Xiujuan Huang,et al.  Ferulic Acid Ameliorates Intrahepatic Triglyceride Accumulation In Vitro But Not in High Fat Diet-Fed C57BL/6 Mice. , 2021, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[36]  Maria-José U. Ferreira.  Natural products in drug discovery and human health , 2021, Phytochemistry Reviews.

[37]  A. R. Silva,et al.  PPAR Gamma: From Definition to Molecular Targets and Therapy of Lung Diseases , 2021, International journal of molecular sciences.

[38]  Xianying Fang,et al.  Echinacoside ameliorates alcohol-induced oxidative stress and hepatic steatosis by affecting SREBP1c/FASN pathway via PPARα. , 2020, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[39]  Z. Ning,et al.  Pharmacokinetics and Safety of Chiglitazar, a Peroxisome Proliferator‐Activated Receptor Pan‐Agonist, in Patients < 65 and ≥ 65 Years With Type 2 Diabetes , 2020, Clinical pharmacology in drug development.

[40]  F. Zhang,et al.  Natural product derived phytochemicals in managing acute lung injury by multiple mechanisms , 2020, Pharmacological Research.

[41]  Tiehua Zhang,et al.  Immunomodulatory activities of polysaccharides from Ganoderma on immune effector cells. , 2020, Food chemistry.

[42]  Tajpreet Kaur,et al.  Stevioside protects against rhabdomyolysis‐induced acute kidney injury through PPAR‐γ agonism in rats , 2020, Drug development research.

[43]  Bhavesh C. Variya,et al.  Antidiabetic potential of gallic acid from Emblica officinalis: Improved glucose transporters and insulin sensitivity through PPAR-γ and Akt signaling. , 2020, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[44]  A. Kappo,et al.  Isoorientin: A dietary flavone with the potential to ameliorate diverse metabolic complications. , 2020, Pharmacological research.

[45]  K. Walsh,et al.  Natural product-derived phytochemicals as potential agents against coronaviruses: A review , 2020, Virus Research.

[46]  Liping Xie,et al.  A concise total synthesis and PPAR activation activity of hericerin from Hericium erinaceum , 2020, The Journal of Antibiotics.

[47]  J. Simal-Gándara,et al.  Dietary polyphenols as antidiabetic agents: Advances and opportunities , 2020, Food Frontiers.

[48]  Y. Mimaki,et al.  Benzofuran and coumarin derivatives from the root of Angelica dahurica and their PPAR-γ ligand-binding activity. , 2020, Phytochemistry.

[49]  Hari Prasad Devkota,et al.  Dietary Flavonoids in the Management of Huntington’s Disease: Mechanism and Clinical Perspective , 2020 .

[50]  Ting Wang,et al.  Bergenin Exerts Hepatoprotective Effects by Inhibiting the Release of Inflammatory Factors, Apoptosis and Autophagy via the PPAR-γ Pathway , 2020, Drug design, development and therapy.

[51]  Tiehua Zhang,et al.  Saponins as modulators of nuclear receptors , 2020, Critical reviews in food science and nutrition.

[52]  F. Koohdani,et al.  Effects of DHA-enriched fish oil on gene expression levels of p53 and NF-κB and PPAR-γ activity in PBMCs of patients with T2DM: A randomized, double-blind, clinical trial. , 2019, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[53]  Kuo-Hu Chen,et al.  Isoflavone Supplements for Menopausal Women: A Systematic Review , 2019, Nutrients.

[54]  Changlin Zhou,et al.  Aesculin protects against DSS-Induced colitis though activating PPARγ and inhibiting NF-кB pathway. , 2019, European journal of pharmacology.

[55]  S. Gibbons,et al.  Acacetin—A simple flavone exhibiting diverse pharmacological activities , 2019, Phytochemistry Letters.

[56]  A. Bitto,et al.  β-Caryophyllene Mitigates Collagen Antibody Induced Arthritis (CAIA) in Mice Through a Cross-Talk between CB2 and PPAR-γ Receptors , 2019, Biomolecules.

[57]  Milad Iranshahy,et al.  Review on plant antimicrobials: a mechanistic viewpoint , 2019, Antimicrobial Resistance & Infection Control.

[58]  M. Mahomoodally,et al.  Combating breast cancer using combination therapy with 3 phytochemicals: Piperine, sulforaphane, and thymoquinone , 2019, Cancer.

[59]  L. Saso,et al.  The influence of alkaloids on oxidative stress and related signaling pathways. , 2019, Free radical biology & medicine.

[60]  A. Ozpinar,et al.  PPAR‐&dgr; and erucic acid in multiple sclerosis and Alzheimer's Disease. Likely benefits in terms of immunity and metabolism , 2019, International immunopharmacology.

[61]  Jiayin Yao,et al.  Gentiopicroside Ameliorates Diabetic Peripheral Neuropathy by Modulating PPAR- Γ/AMPK/ACC Signaling Pathway , 2018, Cellular Physiology and Biochemistry.

[62]  A. Mishra,et al.  Resveratrol: A Double-Edged Sword in Health Benefits , 2018, Biomedicines.

[63]  W. Setzer,et al.  Apigenin: A natural bioactive flavone-type molecule with promising therapeutic function , 2018, Journal of Functional Foods.

[64]  A. Kandhare,et al.  Neuroprotective effect of naringin, a flavone glycoside in quinolinic acid-induced neurotoxicity: Possible role of PPAR-γ, Bax/Bcl-2, and caspase-3. , 2018, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[65]  C. Sirtori,et al.  PPAR Agonists and Metabolic Syndrome: An Established Role? , 2018, International journal of molecular sciences.

[66]  N. Koide,et al.  Therapeutic activity of plant-derived alkaloid conophylline on metabolic syndrome and neurodegenerative disease models , 2018, Human Cell.

[67]  N. El‐Ashmawy,et al.  Upregulation of PPAR-γ mediates the renoprotective effect of omega-3 PUFA and ferulic acid in gentamicin-intoxicated rats. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[68]  S. Epstein,et al.  Insulin resistance and bone: a biological partnership , 2018, Acta Diabetologica.

[69]  Damanpreet Singh,et al.  Iridoid glycosides fraction from Picrorhiza kurroa attenuates cyclophosphamide-induced renal toxicity and peripheral neuropathy via PPAR-γ mediated inhibition of inflammation and apoptosis. , 2017, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[70]  F. Alarcón-Aguilar,et al.  Potential of the chlorogenic acid as multitarget agent: Insulin-secretagogue and PPAR α/γ dual agonist. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[71]  Wei Wang,et al.  Chiglitazar Preferentially Regulates Gene Expression via Configuration-Restricted Binding and Phosphorylation Inhibition of PPARγ , 2017, PPAR research.

[72]  P. Venkateswararao,et al.  Flavonoid: A review on Naringenin , 2017 .

[73]  H. Jang,et al.  Rosiglitazone increases endothelial cell migration and vascular permeability through Akt phosphorylation , 2017, BMC Pharmacology and Toxicology.

[74]  F. Kraemer,et al.  PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ. , 2017, Future cardiology.

[75]  Yanqing Zhang,et al.  Baicalin Attenuates Cardiac Dysfunction and Myocardial Remodeling in a Chronic Pressure-Overload Mice Model , 2017, Cellular Physiology and Biochemistry.

[76]  W. Wahli,et al.  Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome , 2017, Expert opinion on therapeutic targets.

[77]  Z. Abassi,et al.  Does Thiazolidinedione therapy exacerbate fluid retention in congestive heart failure? , 2016, Pharmacology & therapeutics.

[78]  C. Mantzoros,et al.  Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review. , 2016, Metabolism: clinical and experimental.

[79]  S. Grundy.  Metabolic syndrome update. , 2016, Trends in cardiovascular medicine.

[80]  Wei Li,et al.  Picrasidine N Is a Subtype-Selective PPARβ/δ Agonist. , 2016, Journal of natural products.

[81]  Weiliang Zhu,et al.  Bavachinin, as a novel natural pan-PPAR agonist, exhibits unique synergistic effects with synthetic PPAR-γ and PPAR-α agonists on carbohydrate and lipid metabolism in db/db and diet-induced obese mice , 2016, Diabetologia.

[82]  Changwei Qiu,et al.  Betulin suppresses S. aureus-induced mammary gland inflammatory injury by regulating PPAR-γ in mice. , 2015, International immunopharmacology.

[83]  Yujung Jung,et al.  Identification of Eupatilin from Artemisia argyi as a Selective PPARα Agonist Using Affinity Selection Ultrafiltration LC-MS , 2015, Molecules.

[84]  Lin Qiu,et al.  Selective targeting of PPARγ by the natural product chelerythrine with a unique binding mode and improved antidiabetic potency , 2015, Scientific Reports.

[85]  Bingqiao Yang,et al.  Paeoniflorin Protects against Nonalcoholic Fatty Liver Disease Induced by a High-Fat Diet in Mice. , 2015, Biological & pharmaceutical bulletin.

[86]  Zhiqiang Ma,et al.  Astragalin inhibits IL-1β-induced inflammatory mediators production in human osteoarthritis chondrocyte by inhibiting NF-κB and MAPK activation. , 2015, International immunopharmacology.

[87]  S. Chirumbolo.  Genistein as a nature-derived PPAR agonist in adipogenesis and weight gain , 2015, European Journal of Nutrition.

[88]  Huimin Zhao,et al.  Recent advances in natural product discovery. , 2014, Current opinion in biotechnology.

[89]  S. Goyal,et al.  Hesperidin Produces Cardioprotective Activity via PPAR-γ Pathway in Ischemic Heart Disease Model in Diabetic Rats , 2014, PloS one.

[90]  I. Álvarez-González,et al.  Review of natural products with hepatoprotective effects. , 2014, World journal of gastroenterology.

[91]  M. Cooper,et al.  Natural product and natural product derived drugs in clinical trials. , 2014, Natural product reports.

[92]  Manjinder Singh,et al.  Flavones: an important scaffold for medicinal chemistry. , 2014, European journal of medicinal chemistry.

[93]  Z. Liu,et al.  Hydroxysafflor yellow A suppresses liver fibrosis induced by carbon tetrachloride with high-fat diet by regulating PPAR-γ/p38 MAPK signaling , 2014, Pharmaceutical biology.

[94]  Myung‐Suk Kim,et al.  Panduratin A, an activator of PPAR-α/δ, suppresses the development of oxazolone-induced atopic dermatitis-like symptoms in hairless mice. , 2014, Life sciences.

[95]  S. Kersten.  Integrated physiology and systems biology of PPARα , 2014, Molecular metabolism.

[96]  J. Peters,et al.  Activation of Peroxisome Proliferator-Activated Receptor-β/δ (PPAR-β/δ) Inhibits Human Breast Cancer Cell Line Tumorigenicity , 2014, Molecular Cancer Therapeutics.

[97]  R. Brook,et al.  The Peroxisome Proliferator Activated Receptor‐γ Pioglitazone Improves Vascular Function and Decreases Disease Activity in Patients With Rheumatoid Arthritis , 2013, Journal of the American Heart Association.

[98]  S. Noha,et al.  Honokiol: A non-adipogenic PPARγ agonist from nature☆ , 2013, Biochimica et biophysica acta.

[99]  Curtis J Henrich,et al.  Matching the power of high throughput screening to the chemical diversity of natural products. , 2013, Natural product reports.

[100]  D. Grobbee,et al.  Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial. , 2013, American heart journal.

[101]  Shiping Ma,et al.  Formononetin Inhibited the Inflammation of LPS-Induced Acute Lung Injury in Mice Associated with Induction of PPAR Gamma Expression , 2013, Inflammation.

[102]  N. Chi,et al.  Therapeutic Potential of the Natural Product Mangiferin in Metabolic Syndrome , 2013 .

[103]  Sarita Gupta,et al.  Swertiamarin: An Active Lead from Enicostemma littorale Regulates Hepatic and Adipose Tissue Gene Expression by Targeting PPAR-γ and Improves Insulin Sensitivity in Experimental NIDDM Rat Model , 2013, Evidence-based complementary and alternative medicine : eCAM.

[104]  David J Newman,et al.  Natural products: a continuing source of novel drug leads. , 2013, Biochimica et biophysica acta.

[105]  Hailong Zhang,et al.  Ginsenoside Re reduces insulin resistance through activation of PPAR-γ pathway and inhibition of TNF-α production. , 2013, Journal of ethnopharmacology.

[106]  N. Brown,et al.  Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension , 2013, Journal of hypertension.

[107]  W. Deng,et al.  Baicalein, a natural product, selectively activating AMPKα2 and ameliorates metabolic disorder in diet-induced mice , 2012, Molecular and Cellular Endocrinology.

[108]  Adam W. Bero,et al.  Disruption of the Sleep-Wake Cycle and Diurnal Fluctuation of β-Amyloid in Mice with Alzheimer’s Disease Pathology , 2012, Science Translational Medicine.

[109]  Jung Ho Song,et al.  Total synthesis and dual PPARα/γ agonist effects of amorphastilbol and its synthetic derivatives. , 2012, Bioorganic & medicinal chemistry letters.

[110]  Hualiang Jiang,et al.  Molecular Determinants of Magnolol Targeting Both RXRα and PPARγ , 2011, PloS one.

[111]  K. Hwang,et al.  Ursolic acid is a PPAR-α agonist that regulates hepatic lipid metabolism. , 2011, Bioorganic & medicinal chemistry letters.

[112]  Veronica M. W. Gee,et al.  Anticancer activity of thymoquinone in breast cancer cells: possible involvement of PPAR-γ pathway. , 2011, Biochemical pharmacology.

[113]  J.-K. Hwang,et al.  Therapeutic potential of panduratin A, LKB1‐dependent AMP‐activated protein kinase stimulator, with activation of PPARα/δ for the treatment of obesity , 2011, Diabetes, obesity & metabolism.

[114]  R. Brook,et al.  Interleukin 17 as a novel predictor of vascular function in rheumatoid arthritis , 2011, Annals of the rheumatic diseases.

[115]  S. Barnes,et al.  Isoflavones and PPAR Signaling: A Critical Target in Cardiovascular, Metastatic, and Metabolic Disease , 2011, PPAR research.

[116]  A. Verma,et al.  The biological potential of flavones. , 2010, Natural product reports.

[117]  Shing-Hwa Liu,et al.  Honokiol inhibits gastric tumourigenesis by activation of 15‐lipoxygenase‐1 and consequent inhibition of peroxisome proliferator‐activated receptor‐γ and COX‐2‐dependent signals , 2010, British journal of pharmacology.

[118]  S. Nissen,et al.  Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. , 2010, Archives of internal medicine.

[119]  Tetsuro Ito,et al.  Vaticanol C, a resveratrol tetramer, activates PPARα and PPARβ/δ in vitro and in vivo , 2010, Nutrition & metabolism.

[120]  A. Jungbauer,et al.  Potential Health-modulating Effects of Isoflavones and Metabolites via Activation of PPAR and AhR , 2010, Nutrients.

[121]  Shinichi Yokota,et al.  Phenolics from Glycyrrhiza glabra roots and their PPAR-gamma ligand-binding activity. , 2010, Bioorganic & medicinal chemistry.

[122]  K. Abdul Kadir,et al.  Effects of Glycyrrhizic Acid on Peroxisome Proliferator-Activated Receptor Gamma (PPARγ), Lipoprotein Lipase (LPL), Serum Lipid and HOMA-IR in Rats , 2009, PPAR research.

[123]  Yu-Chih Liang,et al.  Osthole, a potential antidiabetic agent, alleviates hyperglycemia in db/db mice. , 2009, Chemico-biological interactions.

[124]  T. H. Huang,et al.  The role of herbal PPAR modulators in the treatment of cardiometabolic syndrome. , 2009, Pharmacological research.

[125]  M. Hanefeld,et al.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial , 2009, The Lancet.

[126]  Dae Young Kwon,et al.  Antiobesity effect of ginsenoside Rg3 involves the AMPK and PPAR‐γ signal pathways , 2009, Phytotherapy research : PTR.

[127]  Y. Cheon,et al.  Antiobesity effects of wild ginseng (Panax ginseng C.A. Meyer) mediated by PPAR‐γ, GLUT4 and LPL in ob/ob mice , 2009, Phytotherapy research : PTR.

[128]  Shenghua Shi,et al.  Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent , 2009, Proceedings of the National Academy of Sciences.

[129]  Jian Peng,et al.  Duration of feeding linseed diet influences peroxisome proliferator-activated receptor γ and tumor necrosis factor gene expression, and muscle mass of growing–finishing barrows , 2008 .

[130]  Yoshitomo Hamuro,et al.  Structure of the intact PPAR-γ–RXR-α nuclear receptor complex on DNA , 2008, Nature.

[131]  Naisheng Bai,et al.  Fenugreek Extract Rich in 4-Hydroxyisoleucine and Trigonelline Activates PPARα and Inhibits LDL Oxidation: Key Mechanisms in Controlling the Metabolic Syndrome , 2008 .

[132]  Otto Sticher,et al.  Natural product isolation. , 2008, Natural product reports.

[133]  Y. Guan,et al.  PPARs and the kidney in metabolic syndrome. , 2008, American journal of physiology. Renal physiology.

[134]  P. Facchini,et al.  Alkaloid biosynthesis: metabolism and trafficking. , 2008, Annual review of plant biology.

[135]  R. Playford,et al.  Comparison of cytokine modulation by natural peroxisome proliferator-activated receptor gamma ligands with synthetic ligands in intestinal-like Caco-2 cells and human dendritic cells--potential for dietary modulation of peroxisome proliferator-activated receptor gamma in intestinal inflammation. , 2008, The American journal of clinical nutrition.

[136]  Noeris K. Salam,et al.  Novel PPAR‐gamma Agonists Identified from a Natural Product Library: A Virtual Screening, Induced‐Fit Docking and Biological Assay Study , 2007, Chemical biology & drug design.

[137]  J. Hoofnagle,et al.  The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis , 2007, Hepatology.

[138]  Yuhao Li,et al.  Gypenoside XLIX, a naturally occurring PPAR-alpha activator, inhibits cytokine-induced vascular cell adhesion molecule-1 expression and activity in human endothelial cells. , 2007, European journal of pharmacology.

[139]  S. Kersten,et al.  PPARα and dyslipidemia , 2007 .

[140]  A. Jacob,et al.  Mechanism of the Anti-inflammatory Effect of Curcumin: PPAR-γ Activation , 2007, PPAR research.

[141]  Jun Ren,et al.  Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus. , 2007, Current diabetes reviews.

[142]  B. Spiegelman,et al.  International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors , 2006, Pharmacological Reviews.

[143]  F. Pattou,et al.  Peroxisome Proliferator–Activated Receptor α Improves Pancreatic Adaptation to Insulin Resistance in Obese Mice and Reduces Lipotoxicity in Human Islets , 2006, Diabetes.

[144]  Y. Matsuzawa.  The metabolic syndrome and adipocytokines , 2006, FEBS letters.

[145]  Mei Hui Liu,et al.  Differential effects of isoflavones, from Astragalus membranaceus and Pueraria thomsonii, on the activation of PPARalpha, PPARgamma, and adipocyte differentiation in vitro. , 2006, The Journal of nutrition.

[146]  Yuhao Li,et al.  Gypenoside XLIX isolated from Gynostemma pentaphyllum inhibits nuclear factor-kappaB activation via a PPAR-alpha-dependent pathway. , 2006, Journal of biomedical science.

[147]  Nayyar Iqbal,et al.  Effects of Rosiglitazone on Lipids, Adipokines, and Inflammatory Markers in Nondiabetic Patients With Low High-Density Lipoprotein Cholesterol and Metabolic Syndrome , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[148]  W. Wahli,et al.  Fluorescence Imaging Reveals the Nuclear Behavior of Peroxisome Proliferator-activated Receptor/Retinoid X Receptor Heterodimers in the Absence and Presence of Ligand*♦ , 2005, Journal of Biological Chemistry.

[149]  M. Pirmohamed,et al.  Phase I Clinical Trial of Oral Curcumin , 2004, Clinical Cancer Research.

[150]  H. Roche,et al.  Conjugated linoleic acid supplementation, insulin sensitivity, and lipoprotein metabolism in patients with type 2 diabetes mellitus. , 2004, The American journal of clinical nutrition.

[151]  W. Wahli,et al.  PPARα governs glycerol metabolism , 2004 .

[152]  H. Kishida,et al.  Phenolics with PPAR-γ ligand-Binding activity obtained from licorice (Glycyrrhiza uralensis Roots) and ameliorative effects of glycyrin on genetically diabetic KK-Ay mice , 2003 .

[153]  Johan Auwerx,et al.  Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[154]  S. Grundy,et al.  The metabolic syndrome , 2003, The Lancet.

[155]  P. Arner,et al.  Treatment with dietary trans10cis12 conjugated linoleic acid causes isomer-specific insulin resistance in obese men with the metabolic syndrome. , 2002, Diabetes care.

[156]  E. Hirsch,et al.  Protective action of the peroxisome proliferator‐activated receptor‐γ agonist pioglitazone in a mouse model of Parkinson's disease , 2002, Journal of neurochemistry.

[157]  Lee-Ming Chuang,et al.  Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. , 2002, Diabetes care.

[158]  B. Staels,et al.  PPARS, metabolic disease and atherosclerosis. , 2001, Pharmacological research.

[159]  J. Auwerx,et al.  Peroxisome Proliferator-activated Receptor-α Regulates Lipid Homeostasis, but Is Not Associated with Obesity , 2001, The Journal of Biological Chemistry.

[160]  M. Pirmohamed,et al.  Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. , 2001, Clinical Cancer Research.

[161]  S. Jee,et al.  Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. , 2001, Anticancer research.

[162]  H. Gronemeyer,et al.  Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. , 2000, Trends in pharmacological sciences.

[163]  J. Auwerx,et al.  Activation of PPARδ alters lipid metabolism in db/db mice , 2000 .

[164]  O. Yu,et al.  Identification and expression of isoflavone synthase, the key enzyme for biosynthesis of isoflavones in legumes , 2000, Nature Biotechnology.

[165]  S. Kato,et al.  [Peroxisome proliferator-activated receptor(PPAR)--structure, function, tissue distribution, gene expression]. , 2000, Nihon rinsho. Japanese journal of clinical medicine.

[166]  M. Mittal,et al.  Hepatocellular Injury in a Patient Receiving Rosiglitazone: A Case Report , 2000, Annals of Internal Medicine.

[167]  S. O’Rahilly,et al.  Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension , 1999, Nature.

[168]  B. Stegelmeier,et al.  Pyrrolizidine alkaloid plants, metabolism and toxicity. , 1999, Journal of natural toxins.

[169]  L. Jendeberg,et al.  Crystal Structure of the Ligand Binding Domain of the Human Nuclear Receptor PPARγ* , 1998, The Journal of Biological Chemistry.

[170]  T. Willson,et al.  Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ , 1998, Nature.

[171]  B. Spiegelman,et al.  Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. , 1996, The Journal of clinical investigation.

[172]  B. Ludvik,et al.  Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. , 1994, The New England journal of medicine.

[173]  A. Mahfoudi,et al.  Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[174]  K. Umesono,et al.  Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors , 1992, Nature.

[175]  Christine Dreyer,et al.  Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors , 1992, Cell.

[176]  I. Issemann,et al.  Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators , 1990, Nature.

[177]  T. Gusdinar,et al.  Docking study of secondary metabolites from Glycyrrhiza glabra as PPAR-γ agonist , 2019, Biointerface Research in Applied Chemistry.

[178]  Azman Abdullah,et al.  A review of flavonoid quercetin: Metabolism, Bioactivity and antioxidant properties , 2014 .

[179]  Harry Martin.  Role of PPAR-gamma in inflammation. Prospects for therapeutic intervention by food components. , 2009, Mutation research.

[180]  E. Barroso,et al.  Peroxisome proliferator-activated receptor (PPAR) beta/delta: a new potential therapeutic target for the treatment of metabolic syndrome. , 2009, Current molecular pharmacology.

[181]  H. Minuk,et al.  Metabolic syndrome. , 2005, Journal of insurance medicine.

[182]  W. Fehr,et al.  Influence of genotype and environment on isoflavone contents of soybean. , 2000 .

[183]  W. Wahli,et al.  Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. , 1996, Endocrinology.